<DOC>
	<DOCNO>NCT00170872</DOCNO>
	<brief_summary>This study test safety , tolerability efficacy lumiracoxib - COX-2 inhibitor- patient primary knee osteoarthritis rheumatoid arthritis .</brief_summary>
	<brief_title>6 Week Open-label Trial With Lumiracoxib 200mg o.d . Primary Knee Osteoarthritis Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Requirement regular NSAID therapy With primary osteoarthritis target knee ( ACR Criteria ) diagnosis rheumatoid arthritis ( ACR Criteria ) Evidence active ulceration UGI tract within 6 month prior screen visit history active bleeding UGI tract within previous 5 year . As well pyloric duodenal obstruction history gastrointestinal parasite . History cardiac cerebral thrombotic/ischemic disease and/or event Patients take additional NSAIDs ( include COX2 inhibitor ) course study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Cox-2</keyword>
	<keyword>lumiracoxib</keyword>
</DOC>